Sang‐Hee Cho

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Yoon‐Koo Kang, Jeong Hwan Yook, Young-Kyu Park et al. · Journal of Clinical Oncology · 2021 · 332 citations · Full text

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Rui‐Hua Xu, Kei Muro, Satoshi Morita et al. · The Lancet Oncology · 2018 · 157 citations

Medicine, Pharmacology, Clinical Trials +10

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

Jun‐Eul Hwang, Hana Kim, Dae‐Eun Kim et al. · BMC Cancer · 2011 · 81 citations · Full text

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

Hyun Jeong Shim, Joo Young Yun, Jun‐Eul Hwang et al. · Cancer Science · 2010 · 75 citations · Full text

Agc Patients, Xrcc1 Polymorphisms, Advanced Gastric Cancer +16

Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer

Woo Kyun Bae, Jun‐Eul Hwang, Hyun Jeong Shim et al. · Cancer Chemotherapy and Pharmacology · 2009 · 72 citations

Medicine, Metronomic Therapy, Nasopharyngeal Cancer +9